GS

Garlapati Suman

Director Director DIN 02483755
DIN 02483755 First appointment May 2009 Primary industry Life Sciences
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 3 historical roles
Total affiliations 3 Since May 2009
Shareholding value β€’β€’β€’β€’ Premium profile

About Garlapati Suman

Data last updated:

Garlapati Suman was a Director at Vigilare Biopharma Private Limited (2014–2020), Director at Genpeutics Technologies Private Limited (from 2009) and Designated Partner at Vigiclinica Llp (from 2016). The companies operate in Life Sciences.

DIN 02483755
Primary Designation Director
Industry Life Sciences
First Appointment 29 May 2009
Oldest Company Age 17 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Vigilare Biopharma Private Limited U72900TG2014PTC095220
Director05 Nov 20142014₹8.59 Cr (FY 2024)Active
Director29 May 20092009Strike Off
Vigiclinica Llp AAH-5914
Designated Partner13 Oct 20162016Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Genpeutics Technologies Private Limited
Vigiclinica Llp
Vigilare Biopharma Private Limited
Premium access

Shareholding and investment profile for Garlapati Suman

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Garlapati Suman

Garlapati Suman was first appointed on 29 May 2009 as Director at Genpeutics Technologies Private Limited. The most recent appointment on record is 13 Oct 2016 at Vigiclinica Llp.

Garlapati Suman held 3 earlier board appointments: Vigilare Biopharma Private Limited (Director, 05 Nov 2014 to 23 Jul 2020); Genpeutics Technologies Private Limited (Director, from 29 May 2009); Vigiclinica Llp (Designated Partner, from 13 Oct 2016).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available